Global Blood Therapeutics hasn’t finished testing its treatment for sickle cell disease, but the South San Francisco, CA-based company thinks it can get a fast-track approval for the once-a-day pill, voxelotor, from the FDA.
That was the company’s message this morning when it presented results from the first half of its key Phase 3 study, known as HOPE. Part A of the study continued voxelotor’s track record from previous studies. In two different doses, the drug significantly boosted levels of the protein hemoglobin, which carries oxygen and is crucial to the healthy function of red blood cells. The news bumped Global… Read more »
UNDERWRITERS AND PARTNERS